TrialDiabetes, obesity & metabolism2022

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.

Kohei Kaku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.